TW200716531A - Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia - Google Patents

Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia

Info

Publication number: TW200716531A
Authority: TW; Taiwan
Prior art keywords: alkyl; cycloalkyl; cyclohexanesulfonyl; derivatives; heterocyclyl
Prior art date: 2005-06-06

Application number

TW095119888A

Other languages

English (en)

Inventor

Wesley Peter Blackaby

Pineiro Jose Luis Castro

Richard Thomas Lewis

Elizabeth Mary Naylor

Leslie Joseph Street

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-06-06

Filing date

2006-06-05

Publication date

2007-05-01

2005-06-06 Priority claimed from GB0511452A external-priority patent/GB0511452D0/en

2005-08-17 Priority claimed from GB0516787A external-priority patent/GB0516787D0/en

2005-12-08 Priority claimed from GB0524968A external-priority patent/GB0524968D0/en

2006-06-05 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2007-05-01 Publication of TW200716531A publication Critical patent/TW200716531A/zh

Links

239000003112 inhibitor Substances 0.000 title abstract 2
201000000980 schizophrenia Diseases 0.000 title abstract 2
102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 title 1
-1 Cyclohexanesulfonyl Chemical class 0.000 title 1
101000972916 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 4
125000000753 cycloalkyl group Chemical group 0.000 abstract 4
125000000623 heterocyclic group Chemical group 0.000 abstract 3
125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
102100023145 Sodium- and chloride-dependent glycine transporter 1 Human genes 0.000 abstract 1
101710083171 Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000003368 amide group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
150000002148 esters Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/70—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a saturated carbon skeleton containing rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/76—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/30—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

TW095119888A 2005-06-06 2006-06-05 Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia TW200716531A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0511452A GB0511452D0 (en)	2005-06-06	2005-06-06	Therapeutic agents
GB0516787A GB0516787D0 (en)	2005-08-17	2005-08-17	Therapeutic agents
GB0524968A GB0524968D0 (en)	2005-12-08	2005-12-08	Therapeutic agents

Publications (1)

Publication Number	Publication Date
TW200716531A true TW200716531A (en)	2007-05-01

Family

ID=36636407

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095119888A TW200716531A (en)	2005-06-06	2006-06-05	Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia

Country Status (10)

Country	Link
US (2)	US7626056B2 (zh)
EP (2)	EP1893566B1 (zh)
JP (1)	JP5281395B2 (zh)
AR (1)	AR057350A1 (zh)
AU (1)	AU2006256583B2 (zh)
CA (1)	CA2609969C (zh)
DO (1)	DOP2006000125A (zh)
PE (1)	PE20061490A1 (zh)
TW (1)	TW200716531A (zh)
WO (2)	WO2006131713A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1684759A4 (en) *	2003-11-12	2009-06-10	Merck & Co Inc	4-phenyl-piperidinosulfonyl-Glycine-TRANSPORTER INHIBITORS
AU2005228133B2 (en) *	2004-03-24	2011-09-08	Merck Sharp & Dohme Corp.	Heteroaryl piperidine glycine transporter inhibitors
AU2005243192A1 (en) *	2004-04-29	2005-11-24	Merck & Co., Inc.	Azetidine glycine transporter inhibitors
WO2005107469A2 (en) *	2004-05-05	2005-11-17	Merck & Co., Inc.	Morpholinyl piperidine glycine transporter inhibitors
AU2005292323B2 (en) *	2004-09-30	2011-06-09	Merck Sharp & Dohme Llc	Cyclopropyl piperidine glycine transporter inhibitors
WO2006067529A1 (en) *	2004-12-21	2006-06-29	Merck Sharp & Dohme Limited	Piperidine and azetidine derivatives as glyt1 inhibitors
PE20061490A1 (es)	2005-06-06	2007-02-09	Merck Sharp & Dohme	Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
AU2006258842B2 (en) *	2005-06-13	2011-09-15	Merck Sharp & Dohme Limited	Therapeutic agents
GB0523998D0 (en) *	2005-11-25	2006-01-04	Merck Sharp & Dohme	Therapeutic agents
JP5377329B2 (ja) *	2007-12-26	2013-12-25	Ｍｓｄ株式会社	スルホニル置換六員環誘導体
CN102762534A (zh) *	2009-09-18	2012-10-31	扎里卡斯药品有限公司	作为钙通道阻断剂的芳基砜衍生物
RS64819B1 (sr) *	2010-07-20	2023-12-29	Minerva Neurosciences Inc	Metode upotrebe derivata cikličnih amida za lečenje šizofrenije i njenih simptoma
US8937900B2 (en)	2010-07-20	2015-01-20	Qualcomm Incorporated	Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
JPWO2014199960A1 (ja) *	2013-06-10	2017-02-23	大正製薬株式会社	グリシントランスポーター阻害物質
EP3134406A1 (en)	2014-04-24	2017-03-01	Dart Neuroscience (Cayman) Ltd	Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors
EP3215500A1 (en)	2014-11-05	2017-09-13	Dart NeuroScience (Cayman) Ltd.	Substituted azetidinyl compounds as glyt1 inhibitors
PL3227273T3 (pl)	2014-12-02	2022-05-30	Minerva Neurosciences, Inc.	Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii
CN106467477A (zh) *	2016-08-26	2017-03-01	天津雅奥科技发展有限公司	一种合成化合物（1‑环丙基‑1‑氰基‑4‑环己酮）的新方法
CN106916089B (zh) *	2017-03-14	2018-10-19	大连九信精细化工有限公司	一种选择性合成顺式4-正戊基环己硫醇的制备方法
IL319156A (en)	2017-06-21	2025-04-01	Minerva Neurosciences Inc	Controlled-release oral dosage forms are resistant to gastric acid.
EP3840835A1 (en)	2018-08-21	2021-06-30	Minerva Neurosciences, Inc.	Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
CN115038690A (zh)	2020-01-31	2022-09-09	索尔维公司	用于制造卤代烷基取代的吡啶化合物的方法
CN114426494B (zh) *	2022-01-13	2023-09-15	江苏海洋大学	一种具有作用于taar激动剂的取代甲胺类衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998024760A1 (en) *	1996-12-03	1998-06-11	Graybill Todd L	Aminobenzenedicarboxylic acid-based combinatorial libraries
SE9704544D0 (sv) *	1997-12-05	1997-12-05	Astra Pharma Prod	Novel compounds
IL162104A0 (en)	2001-12-12	2005-11-20	Hoffmann La Roche	Substituted cyclohexane derivatives
GB0223039D0 (en) *	2002-10-04	2002-11-13	Merck Sharp & Dohme	Therapeutic compounds
FR2861073B1 (fr) *	2003-10-17	2006-01-06	Sanofi Synthelabo	Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
EP1684759A4 (en) *	2003-11-12	2009-06-10	Merck & Co Inc	4-phenyl-piperidinosulfonyl-Glycine-TRANSPORTER INHIBITORS
AU2005228133B2 (en) *	2004-03-24	2011-09-08	Merck Sharp & Dohme Corp.	Heteroaryl piperidine glycine transporter inhibitors
AU2005243192A1 (en) *	2004-04-29	2005-11-24	Merck & Co., Inc.	Azetidine glycine transporter inhibitors
WO2005107469A2 (en) *	2004-05-05	2005-11-17	Merck & Co., Inc.	Morpholinyl piperidine glycine transporter inhibitors
AU2005292323B2 (en) *	2004-09-30	2011-06-09	Merck Sharp & Dohme Llc	Cyclopropyl piperidine glycine transporter inhibitors
WO2006067529A1 (en) *	2004-12-21	2006-06-29	Merck Sharp & Dohme Limited	Piperidine and azetidine derivatives as glyt1 inhibitors
PE20061490A1 (es) *	2005-06-06	2007-02-09	Merck Sharp & Dohme	Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1

2006
- 2006-06-05 PE PE2006000608A patent/PE20061490A1/es not_active Application Discontinuation
- 2006-06-05 JP JP2008514201A patent/JP5281395B2/ja not_active Expired - Fee Related
- 2006-06-05 TW TW095119888A patent/TW200716531A/zh unknown
- 2006-06-05 US US11/446,735 patent/US7626056B2/en active Active
- 2006-06-05 CA CA2609969A patent/CA2609969C/en not_active Expired - Fee Related
- 2006-06-05 WO PCT/GB2006/002052 patent/WO2006131713A1/en not_active Ceased
- 2006-06-05 DO DO2006000125A patent/DOP2006000125A/es unknown
- 2006-06-05 AU AU2006256583A patent/AU2006256583B2/en not_active Ceased
- 2006-06-05 EP EP06744089A patent/EP1893566B1/en active Active
- 2006-06-05 EP EP06744106A patent/EP1891002B1/en active Active
- 2006-06-05 WO PCT/GB2006/002035 patent/WO2006131711A1/en not_active Ceased
- 2006-06-05 AR ARP060102342A patent/AR057350A1/es unknown
2009
- 2009-10-01 US US12/571,904 patent/US7851638B2/en active Active

Also Published As

Publication number	Publication date
EP1893566B1 (en)	2013-02-13
WO2006131713A1 (en)	2006-12-14
PE20061490A1 (es)	2007-02-09
WO2006131711A1 (en)	2006-12-14
AR057350A1 (es)	2007-11-28
US20100029726A1 (en)	2010-02-04
CA2609969A1 (en)	2006-12-14
JP2008542348A (ja)	2008-11-27
US7626056B2 (en)	2009-12-01
AU2006256583B2 (en)	2012-01-12
JP5281395B2 (ja)	2013-09-04
EP1891002A1 (en)	2008-02-27
EP1893566A1 (en)	2008-03-05
EP1891002B1 (en)	2012-05-30
DOP2006000125A (es)	2006-12-31
US7851638B2 (en)	2010-12-14
AU2006256583A1 (en)	2006-12-14
US20060276655A1 (en)	2006-12-07
CA2609969C (en)	2015-10-27

Publication	Publication Date	Title
TW200716531A (en)	2007-05-01	Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
MX2008012404A (es)	2008-10-09	Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g.
MY148566A (en)	2013-04-30	Crystalline solvates and complexes of (is) -1, 5- anhydro-1 -c-(3-( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
MX2012002542A (es)	2012-04-02	Compuestos y composiciones como inhibidores de cinasa de proteina.
EA200601896A1 (ru)	2007-02-27	Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv
MXPA05011166A (es)	2005-12-14	Antagonistas del receptor del peptido relacionado con el gen de la calcitonina.
GEP20125456B (en)	2012-03-26	Azetidines as mek inhibitors for the treatment of proliferative diseases
TW200728305A (en)	2007-08-01	Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
BRPI0707491B8 (pt)	2021-05-25	compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
NZ533310A (en)	2004-12-24	Benzimidazoles useful as protein kinase inhibitors
NZ579296A (en)	2012-10-26	Spirocyclic compounds as inhibitors of serine proteases for the treatment of HCV infections
TW200510317A (en)	2005-03-16	Caspase inhibitors and uses thereof
MX2009003227A (es)	2009-04-06	Moduladores de los receptores de glutamato metabotropicos 5(mglur5).
HRP20070430T3 (en)	2007-11-30	(3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
ATE538651T1 (de)	2012-01-15	Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
MX2007007103A (es)	2008-03-10	Derivados espiro como inhibidores de lipoxigenasa.
TW200612936A (en)	2006-05-01	Indole derivatives
IL183373A0 (en)	2007-09-20	3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
MX2009006473A (es)	2009-08-25	Inhibidores de receptor vainilloide de bencimidazol.
MX2007004248A (es)	2007-06-12	Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
MX2011006560A (es)	2011-08-03	Derivados heterociclicos fucionados con oxadiazola utiles para el tratamiento de esclerosis multiple.
IL195016A0 (en)	2009-08-03	1h-indol-5-yl-piperazin-1-yl-methanone derivatives
MY158069A (en)	2016-08-30	Tricyclic compound and pharmaceutical use thereof
ATE476431T1 (de)	2010-08-15	Piperidin- und azetidinderivate als glyt1- inhibitoren
MXPA05010020A (es)	2005-11-17	Derivados de oxamida.